Instead, Tan and colleagues employed both Sanger sequencing (SS) and ddPCR to analyze the clone composition and dynamic evolution of KIT double gene mutations in core binding factor (CBF)-AML patients, revealing that the double mutations can occur in either the same or different clones and the latter may generate a different sensitivity to CBF-AML treatment [45]. This evidence concerns the gene KIT and acute myeloid leukemia.